By Ben Glickman

Harpoon Therapeutics said on Wednesday that AbbVie won't exercise its exclusive license option on Harpoon's HPN217 program.

The South San Francisco, Calif.-based immuno-oncology company said that AbbVie had the option under an agreement between the two companies, which is set to expire Oct. 12. Harpoon said that it plans to complete the current Phase 1 trial in order to continue development.

Harpoon's HPN217 program targets B cell maturation antigen. Chief Executive Julie Eastland said that the preliminary data "continue to be encouraging with a favorable safety profile."

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

September 13, 2023 16:40 ET (20:40 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Harpoon Therapeutics Charts.
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Harpoon Therapeutics Charts.